Prediction of survival by applying current prognostic models in diffuse large B-cell lymphoma treated with R-CHOP followed by autologous transplantationopen access
- Authors
- Lee, Hong Ghi; Kim, Sung-Yong; Kim, Inho; Kim, Yeo-Kyeoung; Kim, Jeong-A; Kim, Yang Soo; Lee, Ho Sup; Park, Jinny; Kim, Seok Jin; Shim, Hyeok; Eom, Hyeon Seok; Park, Byeong-Bae; Lee, Junglim; Park, Sung Kyu; Cheong, June-Won; Park, Keon Woo
- Issue Date
- Sep-2015
- Publisher
- KOREAN SOC HEMATOLOGY
- Keywords
- Diffuse large B-cell lymphoma; Hematopoietic stem cell transplantation; Autologous transplantation; Rituximab; Prognostic groups
- Citation
- BLOOD RESEARCH, v.50, no.3, pp.160 - 166
- Indexed
- SCOPUS
KCI
- Journal Title
- BLOOD RESEARCH
- Volume
- 50
- Number
- 3
- Start Page
- 160
- End Page
- 166
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/156462
- DOI
- 10.5045/br.2015.50.3.160
- ISSN
- 2287-979X
- Abstract
- Background Among the currently available prognostic models for diffuse large B-cell lymphoma (DLBCL), we investigated to determine which is most adoptable for DLBCL patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) followed by upfront autologous stem cell transplantation (auto-SCT). Methods We retrospectively evaluated survival differences among risk groups based on the International Prognostic Index (IPI), the age-adjusted IPI (aaIPI), the revised IPI (R-IPI), and the National Comprehensive Cancer Network IPI (NCCN-IPI) at diagnosis in 63 CD20-positive DLBCL patients treated with R-CHOP followed by upfront auto-SCT. Results At the time of auto-SCT, 74.6% and 25.4% of patients had achieved complete remission and partial remission after R-CHOP, respectively. As a whole, the 5-year overall (OS) and progression-free survival (PFS) rates were 78.8% and 74.2%, respectively. The 5-year OS and PFS rates according to the IPI, aaIPI, R-IPI, and NCCN-IPI did not significantly differ among the risk groups for each prognostic model (P-values for OS: 0.255, 0.337, 0.881, and 0.803, respectively; P-values for PFS: 0.177, 0.904, 0.295, and 0.609, respectively). Conclusion There was no ideal prognostic model among those currently available for CD20-positive DLBCL patients treated with R-CHOP followed by upfront auto-SCT.
- Files in This Item
-
- Appears in
Collections - 서울 의과대학 > 서울 내과학교실 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/156462)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.